EVOKE PHARMA INC
COM NEW · CUSIP 30049G203
0
institutional holders
-17 vs Q2 2024
—reported value*
0 new
0 added
0 reduced
16 sold out
net sold ≈ $2.0m (-3.8m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q3 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 12 |
| Q4 2022 | 14 |
| Q1 2023 | 13 |
| Q2 2023 | 12 |
| Q3 2023 | 12 |
| Q4 2023 | 12 |
| Q1 2024 | 16 |
| Q2 2024 | 17 |
| Q3 2024 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 4 | 4 |
| Q1 2023 | 4 | 4 |
| Q2 2023 | 3 | 3 |
| Q3 2023 | 4 | 0 |
| Q4 2023 | 4 | 2 |
| Q1 2024 | 9 | 4 |
| Q2 2024 | 7 | 5 |
| Q3 2024 | 0 | 16 |
Biggest buyers
| None |
Biggest sellers
| Nantahala Capital Management, LLC | Sold out | -1.4m |
| AIGH Capital Management LLC | Sold out | -846.6k |
| Bleichroeder LP | Sold out | -825.0k |
| Altium Capital Management LLC | Sold out | -692.4k |
| GEODE CAPITAL MANAGEMENT, LLC | Sold out | -49.7k |
| VANGUARD GROUP INC | Sold out | -29.9k |
| CITADEL ADVISORS LLC | Sold out | -11.9k |
| STATE STREET CORP | Sold out | -10.7k |
| Tower Research Capital LLC (TRC) | Sold out | -7.5k |
| UBS Group AG | Sold out | -1.1k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Nantahala Capital Management, LLC
13D · may seek influence
filed 2025-02-03
Stated purposeItem 4 is hereby supplemented by the addition of the following disclosure: The Reporting Persons have begun discussions with the Issuer regarding the selection of a second designee to the Issuer's board of directors pursuant to the September 2024 Letter Agreement. Upon appointment of the Reporting Persons' designee to the Issuer's board of directors, the Issuer will be required to disclose certain information concerning the designee in a Current Report filed with the SEC on Form 8-K. Full filing |
16.0% |
| Bleichroeder LP 13G · institution no change · filed 2025-03-24 | 10.0% |
Holders, Q3 2024
| Manager | Shares | Change |
|---|